Vunakizumab
In VENuS, vunakizumab is given subcutaneously as 120 mg in 1 mL, while placebo is matched sterile saline. Participants receive vunakizumab or placebo every 4 weeks for 24 weeks, with more frequent dosing in the first 4 weeks. Vunakizumab w…
1 sources - 5 claims
In VENuS, vunakizumab is given subcutaneously as 120 mg in 1 mL, while placebo is matched sterile saline. Participants receive vunakizumab or placebo every 4 weeks for 24 weeks, with more frequent dosing in the first 4 weeks. Vunakizumab was approved in China in August 2024 for adults with moderate-to-severe plaque psoriasis who are candidates for systemic therapy or phototherapy. Vunakizumab is a recombinant humanized monoclonal antibody targeting interleukin-17A. Vunakizumab is being developed by Suzhou Suncadia Biopharmaceutical for systemic treatment of autoimmune diseases related to the IL-17 pathway.